CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?

We expect CRISPR Therapeutics (CRSP) to surpass expectations when it reports third-quarter 2024 results. In the last reported quarter, the company missed on earnings by 8.76%. The Zacks Consensus Estimate for sales is pinned at $6.4 million, while the same for earnings is pegged at a loss of $1.33 per share. Factors Shaping CRSP's Upcoming Results CRISPR Therapeutics' top line currently includes grants and collaboration revenues from its partnership with large-cap biotech Vertex Pharmaceuticals (VRTX) . CRS ...